GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (NAS:TWST) » Definitions » Equity-to-Asset

Twist Bioscience (Twist Bioscience) Equity-to-Asset

: 0.81 (As of Dec. 2023) 中文
View and export this data going back to 2018. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Twist Bioscience's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $590.0 Mil. Twist Bioscience's Total Assets for the quarter that ended in Dec. 2023 was $732.8 Mil. Therefore, Twist Bioscience's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.81.

The historical rank and industry rank for Twist Bioscience's Equity-to-Asset or its related term are showing as below:

TWST' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.74   Med: 0.82   Max: 0.91
Current: 0.81

During the past 8 years, the highest Equity to Asset Ratio of Twist Bioscience was 0.91. The lowest was -1.74. And the median was 0.82.

TWST's Equity-to-Asset is ranked better than
84.94% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58 vs TWST: 0.81

Twist Bioscience Equity-to-Asset Historical Data

The historical data trend for Twist Bioscience's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only 0.81 0.84 0.83 0.82 0.80

Twist Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.82 0.81 0.80 0.81

Competitive Comparison

For the Diagnostics & Research subindustry, Twist Bioscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Twist Bioscience Equity-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's Equity-to-Asset falls into.



Twist Bioscience Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Twist Bioscience's Equity to Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Equity to Asset (A: Sep. 2023 )=Total Stockholders Equity/Total Assets
=623.432/776.403
=0.80

Twist Bioscience's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=590.042/732.815
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Twist Bioscience  (NAS:TWST) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Twist Bioscience Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Twist Bioscience (Twist Bioscience) Business Description

Traded in Other Exchanges
Address
681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Executives
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Dennis Cho officer: See Remarks C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Melissa A. Starovasnik director C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jan Johannessen director 5555 NE MOORE CT., HILLSBORO OR 97124
William Banyai director, officer: Chief Operating Officer C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Paula Green officer: VP of Human Resources C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
James M Thorburn officer: Chief Financial Officer C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Robert Chess director
Patrick John Finn officer: VP of Sales and Marketing C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Emily M. Leproust director, officer: President & CEO C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Patrick Weiss officer: VP of Operations C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Keith Crandell director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kevin Bruce Yankton officer: Chief Accounting Officer 1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104
Mark Daniels officer: Chief Compliance Officer & GC C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158